The role of interleukin-6 in malignant mesothelioma

Por Abdul Rahim, Siti N., Ho, Gwo Y., Coward, Jermaine I.G.
Publicado no Transl Lung Cancer Res (2015)

Recurrent left chest mass: a case report

Por McCague, Andrew, Bowman, Nina, Navarro, Raphael, Kong, Lawrence
Publicado no Transl Lung Cancer Res (2013)

The past, present and future of immunotherapy against tumor

Por Jiang, Tao, Zhou, Caicun
Publicado no Transl Lung Cancer Res (2015)

Novel systemic therapy against malignant pleural mesothelioma

Por Mancuso, Michael R., Neal, Joel W.
Publicado no Transl Lung Cancer Res (2017)

Update on the management of malignant peritoneal mesothelioma

Por Sugarbaker, Paul H.
Publicado no Transl Lung Cancer Res (2018)

The importance of the regimen of screening in maximizing the benefit and minimizing the harms

Por Henschke, Claudia I., Li, Kunwei, Yip, Rowena, Salvatore, Mary, Yankelevitz, David F.
Publicado no Ann Transl Med (2016)

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Por Chen, Zhongjian, Gaudino, Giovanni, Pass, Harvey I., Carbone, Michele, Yang, Haining
Publicado no Transl Lung Cancer Res (2017)

Risk assessment in relation to the detection of small pulmonary nodules

Por Field, John K., Marcus, Michael W., Oudkerk, Matthijs
Publicado no Transl Lung Cancer Res (2017)

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?

Por Kobayashi, Yoshihisa, Mitsudomi, Tetsuya
Publicado no Transl Lung Cancer Res (2013)

Interlobar fixation using TachoSil(®): a novel technique

Por Fiorelli, Alfonso, Scaramuzzi, Roberto, Costanzo, Saveria, Volpicelli, Antonio, Santini, Mario
Publicado no Transl Lung Cancer Res (2015)

Predicting resistance by selection of signaling pathways

Por Karachaliou, Niki, Rosell, Rafael, Molina, Miguel Angel, Viteri, Santiago
Publicado no Transl Lung Cancer Res (2014)

O2. Frequency of EGFR gene mutations in patients with NSCLC in Czech Republic

Por Kultan, Juraj, Kolek, Vitezslav, Fiala, Ondrej, Fínek, Jindrich, Pešek, Miloš, Šatánková, Monika, Skrickova, Jana, Bortlicek, Zbynek, Zbožínková, Zuzana
Publicado no Transl Lung Cancer Res (2014)

PiggyBac transposon vectors: the tools of the human gene encoding

Por Zhao, Shuang, Jiang, Enze, Chen, Shuangshuang, Gu, Yuan, Shangguan, Anna Junjie, Lv, Tangfeng, Luo, Liguo, Yu, Zhenghong
Publicado no Transl Lung Cancer Res (2016)

Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma

Por Wu, Licun, de Perrot, Marc
Publicado no Transl Lung Cancer Res (2017)

Current chemotherapy strategies in malignant pleural mesothelioma

Por de Gooijer, Cornedine Jannette, Baas, Paul, Burgers, Jacobus Adrianus
Publicado no Transl Lung Cancer Res (2018)

Post-operative radiation therapy

Por Paumier, Amaury, Le Péchoux, Cécile
Publicado no Transl Lung Cancer Res (2013)

O3. Registry study in NSCLC patients with EGFR, ALK, or ROS1 mutations

Por Filipits, Martin
Publicado no Transl Lung Cancer Res (2014)

The role of PRRX1 in the apoptosis of A549 cells induced by cisplatin

Por Zhu, Hongbin, Sun, Gengyun, Dong, Jiahui, Fei, Liming
Publicado no Am J Transl Res (2017)

P20. The role of statins in patients with advanced NSCLC harboring KRAS mutation treated with EGFR-TKIs

Por Fiala, Ondrej, Pesek, Milos, Finek, Jindrich, Benesova, Lucie, Minarik, Marek, Bortlicek, Zbynek
Publicado no Transl Lung Cancer Res (2014)

The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey

Por Ben Bouazza, Youssef, Van Meerbeeck, Jan P.
Publicado no Transl Lung Cancer Res (2018)